Zyme Solutions
Supply Chain Software | Strategic Digital Supply Chain | E2open
About Zyme Solutions
E2open operates in the supply chain management sector, providing a comprehensive software platform that connects demand to supply and planning to execution. The company serves a diverse range of clients including manufacturers, retailers, and logistics providers, helping them to optimize their supply chains and improve efficiency. E2open's business model is based on a subscription service, where clients pay for access to its cloud-based software solutions. The platform leverages artificial intelligence to offer real-time insights and decision-making capabilities, enhancing agility and resilience in supply chain operations. E2open's software suite covers all modes of transportation and regions, ensuring end-to-end visibility and control. The company generates revenue through subscription fees, data transmission services, and additional user access. E2open is recognized as a leader in the supply chain software industry, consistently ranking high in industry value matrices. The company recently announced plans to become publicly traded through a combination with CC Neuberger Principal Holdings I.
Source: Dealroom company dataAt a glance
- Founded
- 2000
- Headquarters
- United States
- Sector
- Other B2B Software
Knowledge graph
More headlines
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A1 investor entered at this stage
Artiman Ventures
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Zyme Solutions on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Zyme Solutions on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.